Shaik Shahanaz Parveen, Karan Hasnain Hyder, Singh Arkaja, Attuluri Sai Kiran, Khan Afnan Akram Nawaz, Zahid Fazila, Patil Dhrumil
Junior Resident, Internal Medicine, DR. Y.S.R University of Health Sciences, Andhra Pradesh, India.
Resident, Internal Medicine, San Joaquin General Hospital,French Camp, CA, United States.
Curr Probl Cardiol. 2024 Jan;49(1 Pt C):102155. doi: 10.1016/j.cpcardiol.2023.102155. Epub 2023 Oct 20.
Heart failure characterized by preserved ejection fraction (HFpEF) poses a substantial challenge to healthcare systems worldwide and the diagnostic algorithms used currently mirror those utilized for reduced Ejection Fraction (HFrEF). This literature review aims to explore the diagnostic and prognostic credibility of numerous emerging biomarkers associated with HFpEF. We conducted a thorough analysis of the available medical literature and selected the biomarkers which yielded the maximum amount of published information. After reviewing the current literature we conclude that there are no biomarkers at present which are superior to natriuretic peptides in terms of diagnosis and prognosis of HFpEF. However biomarkers like Suppression of tumorigenicity2, Galectin3 and microRNAs are promising and can be researched further for future use. Although newer individual biomarkers may not be useful in diagnosing and prognosis of HFpEF, we believe that a specific biomarker profile may be identified in each phenotype,which can be used in future.
射血分数保留的心力衰竭（HFpEF）给全球医疗系统带来了巨大挑战，目前使用的诊断算法与用于射血分数降低的心力衰竭（HFrEF）的算法相同。这篇文献综述旨在探讨与HFpEF相关的众多新兴生物标志物的诊断和预后可信度。我们对现有医学文献进行了全面分析，并选择了产生最多已发表信息的生物标志物。在回顾当前文献后，我们得出结论，就HFpEF的诊断和预后而言，目前没有生物标志物优于利钠肽。然而，如抑瘤素2、半乳凝素3和微小RNA等生物标志物很有前景，可以进一步研究以供未来使用。虽然新的单个生物标志物可能对HFpEF的诊断和预后无用，但我们相信可以在每种表型中识别出特定的生物标志物谱，供未来使用。
